Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q1 2018 call → NOWe need to determine if management conveys that the company is small and what is happening now is disproportionately large relative to that smallness. Look for statements about current activity, demand, commitments arriving at scale large relative to company size. Examples: outsized percentage growth due to small base, single product or market rivaling current size, etc. In the transcript, management discusses wearables growth, e-commerce growth, etc. They mention wearables nearly 20% of sales, up from 8% last year. They talk about growth rates. But do they convey that the company is small relative to the opportunity? They mention "we have something like a 5% or 6% share globally of the watch business. If we get that of what's expected to be in wearables, a $33 billion business in three years, it could be a very significant business for us." That is about market share and potential, but is that current? They say "we have something like a 5% or 6% share" - that's current. But the $33 billion is a forecast. They also say "we're in a position to do as much as we can" - that's prospective. The question asks if management conveys that current activity, demand, or commitments are arriving at a scale large relative to the company's small size. They mention wearables growth of 97% in Q1, e-commerce up 50%, etc. But do they explicitly contrast the size of the company with the size of what's arriving? They say "we are in a position with both traditional watches... and wearables... a great global distribution platform" - that's not about disproportion. They also mention "our direct e-commerce business continued to build nicely. Sales in this channel were up nearly 50% in the quarter versus last year." That's strong growth but not necessarily disproportionate relative to company size. The company has $2.4B in sales? Actually they had $569M in Q1, so annualized ~$2.3B. They are not tiny. They are a major player in watches. The question asks if the company is small relative to what is happening. They don't say "we are small" or "this is large relative to our size." They talk about growth rates but that's normal. The example given: "the same absolute wins keep translating into outsized percentage change because the base is still small" - but they don't say that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.